ABSTRACT: This paper examines National Institutes of Health (NIH) pediatric research spending in absolute terms and relative to the doubling of the NIH overall budget between fiscal years 1998 and 2003. Pediatric spending increased by an average annual rate of 12.8 percent during the doubling period (almost on par with the NIH average annual growth rate of 14.7 percent). However, the proportion of the total NIH budget devoted to the pediatric portfolio declined from 12.3 to 11.3 percent. We offer recommendations for implementing existing commitments to strengthen the pediatric research portfolio and to protect the gains of the doubling period.
T h e a ll o c at i o n o f f e d e r a l d o ll a r s for the support of dependent populations has become a major policy concern. Much of the previous attention focused on the economic well-being of children and the elderly-in particular, the declining impoverishment of the elderly and the growing poverty among children over the past half-century. 1 Trends in federal spending on both groups, reported in absolute terms and relative to each other, show evidence of growing intergenerational inequity, leading to increased concern about whether the projected growth in federal spending on health programs for the elderly will come at the expense of credible commitments to programs for children. 2 With that broader debate in mind, we report on the status of the National Institutes of Health (NIH) pediatric research portfolio in absolute terms and relative to the overall NIH budget during the doubling period (fiscal years 1998-2003). We avoid framing NIH appropriations in terms of competition between children and adults for scarce biomedical research dollars. Instead, we ask whether a rising budgetary tide lifted all boats: How has the pediatric portfolio fared in the recent era of rapid overall NIH growth?
Congress has expressed particular interest in the status of pediatric spending and specifically requested that NIH develop performance indicators to measure its progress toward achieving a stronger pediatric portfolio. This paper is a systematic effort to examine the status of the pediatric portfolio during the doubling period, when the overall NIH budget increased by an actual cumulative growth rate of 98.3 percent (75.7 percent in inflation-adjusted terms).
We also highlight the status of the pediatric portfolio within four institutes: National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); National Institute of Neurological Diseases and Stroke (NINDS); and National Human Genome Research Institute (NHGRI). We use these examples to illustrate the benefits of quantifying pediatric spending to assess progress as well as the dangers of drawing conclusions about limited pediatric spending without accounting for the benefits of biomedical research, which are often spread over subpopulations in undifferentiated ways.
Pessimistic assumptions about future annual growth in federal discretionary spending will prove important for understanding the status of the pediatric portfolio over the next decade. The dramatic increase in pediatric spending has permitted NIH to fund record levels of new research and therefore to accumulate a sizable commitment base. We conclude with a set of recommendations for implementing existing commitments to strengthen the NIH pediatric research portfolio and to protect the gains of the doubling period.
Background
n Federal research efforts. Numerous federal research efforts focused on child health during the 1990s. 3 Concurrently, there was increasing congressional concern about the "inadequate attention and resources" that NIH was devoting to pediatric research. 4 In response, NIH issued its first pediatric research report in 1996, which contained a stated commitment "to use a variety of methods" to evaluate Institutes and Centers' (ICs') progress "in achieving a strengthened portfolio in research on children." 5 Congress also urged NIH to establish guidelines for including children in all clinical research trials. NICHD and the American Academy of Pediatrics concurred, and in 1998 NIH released formal guidelines to this end. 6 n Mental health. Increased attention also was focused on child and adolescent mental health in the 1990s. Pediatric research lagged behind that in other subspecialties, largely because of pharmaceutical companies' indifference to marketing psychotropic drugs to children and concerns about the ethics of including children in research. Childhood psychopathology emphasized psychodynamic analysis, and, thus, biomedical and psychopharmacologic research was considered unnecessary, potentially dangerous to children, and misguided. 
Measuring The Pediatric Research Portfolio
High annual NIH growth rates have been accompanied by intensified interest in the internal allocation of funds. The selection of research program areas to be funded remains the responsibility of NIH, based on a system of investigatorinitiated projects selected through merit-based peer review. 9 Many factors are considered, including public health needs and scientific opportunity. 10 Prior efforts to analyze spending focused on the flow of dollars to academic pediatric departments rather than on the pediatric portfolio.
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In this study, we did not attempt to determine whether the amount of funding that NIH awards for research on particular pediatric diseases was commensurate with measures of the burden of disease (prevalence, incidence, use of resources and costs, mortality, morbidity, and so forth). We also recognize that the degree of match between funding and disease burden is sensitive to the measure being used and that advocacy groups for specific diseases can emphasize data derived via a variety of different methods. 12 NIH has an obligation to respond to public health needs, but calculating these needs is very difficult, and there is not always a clear correlation between spending and outcomes. 13 NIH defines pediatric research as "all categories of biomedical research (basic, clinical, epidemiological, behavioral, prevention, treatment, diagnosis, as well as outcomes and health services) that relate to diseases, conditions, or the health/ development of [people] up to age 21." 14 In FY 1995 the NIH Budget Office directed , an extraordinary commitment to accelerate appropriations, which over the previous four decades had doubled every ten years. NIH funding had increased at an average annual rate of 9 percent between FY 1971 and FY 1998. 15 In FY 1994, except for a double-digit increase for AIDS and breast cancer research, the NIH budget was static or contracting in real dollars. 16 It increased by an average annual rate of 5.8 percent between FY 1993 and FY 1997. The pediatric portfolio increased by an average annual rate of 4.7 percent.
n Pediatric spending. During the doubling period, NIH appropriations increased at an average annual rate of 14.7 percent. Pediatric spending increased by an average annual rate of 12. Although the data show that pediatric research enjoyed a share of the benefits of the doubling period, the proportion of the NIH budget devoted to the pediatric portfolio declined slightly, from 12.3 to 11.3 percent, down from 13.1 percent in 1993. Thus, while overall and pediatric spending both increased in nominal and real terms, the proportion devoted to pediatrics remained flat, as it has done since FY 1993 (Exhibit 2). 
percent). NIMH is one of a few
ICs whose pediatric spending growth rate well exceeded the institute's overall rate during the doubling period (Exhibit 5). Much of the newly committed funding went to studies of depression and anxiety in children and adolescents. It is difficult to determine whether this sizable increase is the result of a growing incidence of children's mental disorders or a contributor to their identification and diagnosis.
n Low spenders. NINDS and NHGRI offer examples of ICs with pediatric spending that is below the NIH average (defined as a percentage of the NIH pediatric portfolio). However, data from each illustrate the complexities of quantifying pediatric spending as well as the danger of drawing inappropriate inferences about the implications of such spending for the status of their portfolios.
NINDS. NINDS had one of the largest overall budget increases during the doubling period, 86.6 percent. In part, this reflects advances in the understanding of neurological diseases and recognition of their strong impact on families. However, NINDS' pediatric spending experienced more modest growth of 35.6 percentless than half the ICs' rate (Exhibit 5). The proportion of the NINDS budget awarded to pediatrics decreased from 11.3 percent to 9. Why has NINDS' pediatric spending fallen if, like other ICs, it makes no allocation of funds by subpopulation? Some of the decrease could represent a problem with labeling what research is relevant to pediatric neurological diseases. Other changes have also played a role. The number of child neurologists has been stagnant during the past decade, while the demand for clinical services has ballooned. NINDS is attempting to encourage more child neurologists to choose research careers by funding the K-12 Neurological Sciences Academic Development Award. The effectiveness of this program remains unknown.
In addition, clinical studies of children usually require multicenter collaboration. NINDS and professional child neurology organizations have not been able to organize many collaborative efforts. NINDS has sponsored workshops to help in-vestigators develop directions for collaborative research, but the resulting recommendations have led to projects only infrequently. For example, the NINDS Workshop/Report on Perinatal and Childhood Stroke recommended a multidisciplinary collaborative effort. Although professionals have met to plan research, no funded collaborative studies are forthcoming. Many studies of children's neurological diseases have been organized under the sponsorship of the pharmaceutical industry, especially when this was required by the Food and Drug Administration (FDA). These trends have resulted in fewer investigators and studies that bring advances in basic science to children with neurological diseases.
NHGRI. NHGRI represents a case where quantification of pediatric spending can underestimate the impact of biomedical research that is not specifically reported as part of the official pediatric portfolio. For example, NHGRI spent $25.3 million on pediatric research in FY 2004, just 5.3 percent of its budget. NHGRI's budget more than doubled (113.6 percent) and its pediatric spending increased by 54 percent during the doubling period (Exhibit 5). However, NHGRI's research has implications for pediatric populations, although it is not counted as pediatric spending per se. As opposed to other ICs, NHGRI provides resources for biomedical research with a broad array of applications, such as the effort to map the human genome sequence. This is typical of much of what NHGRI does, including such initiatives as the Encyclopedia of DNA Elements (ENCODE) and the Haplotype map (HapMap). This "nonpediatric" research will have important implications for advancing knowledge of childhood disorders. 17 Caveats On Interpreting Spending Trends n Diffuse research categories. In drawing inferences from aggregate research spending patterns, we note that there is always a challenge in determining the "appropriate" amount of spending on a particular subpopulation or disease. In addition, more and more biomedical research has implications that can be generalized across diseases, organs, and age groups, and this can frustrate any true effort to "count" them under any single disease or subpopulation biomedical research category.
n Clinical research. The data reported include NIH support for research in developmental biology and clinical pediatrics. Thus, developmental biology alone could account for the steady growth rate of the pediatric portfolio. Although this work may lead to new insights into the pathophysiology of diseases that affect children, and hence to new ways to diagnose and treat them, many clinical researchers remain concerned that we are not applying what we already know. Also, the lack of integration of research efforts into centers where basic and clinical scientists research and care for children with complex medical needs compounds the difficulty of performing high-quality, outcomes-based clinical and basic science research.
n Bioterrorism spending. Bioterrorism took a big share of NIH appropriation growth in the final years of the doubling period, and the shares of the overall increase going to pediatric-related research areas have likely dropped off. For example, The recent growth of the NIH budget and its pediatric portfolio has permitted ICs to fund record levels of research and therefore to accumulate a substantial commitment base. The challenge for NIH will be to balance current commitments, new projects, and funding of new investigators. Management of that base will make NIH vulnerable if funding levels remain static. To protect the gains achieved and to capitalize on recent commitments to strengthen the pediatric portfolio, we recommend the following.
n Fund NIH to exceed biomedical inflation. Congress appropriated a 3. research inflation tends to exceed the Consumer Price Index (CPI) by approximately 1.5 percent per year. Unless Congress provides annual increases that well exceed the BRDPI rates, NIH and the pediatric-specific commitments it made during the doubling period will become increasingly vulnerable. n Fund the PRI with specific appropriations. The main purpose of the PRI was to increase existing support for pediatric research. While Congress authorized $50 million to support the PRI in FY 2001 and "such sums as may be necessary" for FY [2002] [2003] [2004] [2005] , to date there have been no specific PRI appropriations. According to a key staffer, Congress never intended to make earmarked appropriations, consistent with its usual practice of funding ICs but not disease areas or subpopulations. Accordingly, it was expected that NIH would allocate dollars from within its overall budget to fund research consistent with the PRI. If the PRI is to be supported with dedicated dollars that represent new funding, supplemental appropriations are the only mechanism by which the pediatric portfolio can expand beyond its "fixed" slice of the budgetary pie.
n Support the NIH child inclusion policy and report on its performance. With a static proportion of funding awarded to pediatric research, including children in all relevant clinical research will become increasingly important. There has never been any effort to evaluate the impact of or develop performance indicators for NIH's child inclusion policy. Because children are counted in numbers of research subjects along with adults, retrospective evaluation may be difficult. It is important, if only prospectively, to know whether the NIH guidelines can be effective and to recommend ways to strengthen the inclusion of children in future research.
n Examine and evaluate the NCS's budgetary trade-offs. NICHD's FY 2005 budget request includes planning dollars for the National Children's Study (NCS) but not funding to launch it. Congress has yet to allocate any specific additional appropriations for study implementation. Excluding expenditures for analysis and reporting, estimated total implementation costs are approximately $2.3 billion (not adjusted for inflation). For recruitment and follow-up during pregnancy and infancy, costs increase to a maximum of $151 million in 2007, then decrease to approximately $93 million per year from 2010 to completion in 2028. 19 In the current era of tight budgets, it is inevitable that internal funding designated for the study would take money away from other program research areas. Without additional appropriations or nongovernmental support, it is highly unlikely that NICHD, as the lead agency, can move beyond the planning stage.
n Broaden the life-cycle focus of pediatric research. The tendency to define all economic and health well-being issues as distributional problems among age groups at a slice in time must be avoided. The pediatric community needs to emphasize the potential for investments in pediatric research to influence health and human development across the life cycle. For example, a more complete understanding of the plasticity of the brain might contribute to methods for educating children and preserving cognitive function throughout life. Also, an understanding of the rela-tionship between genetic variation and disease risk promises to change greatly the prevention and treatment of childhood and adult illnesses. Pediatricians and advocacy groups will need to form partnerships with their adult-focused research and policy colleagues and offer new conceptual arguments (and evidence) about the longer-term benefits of today's investment in the health and well-being of our children. 
